The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis and uterine fibroids , as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. This role provides independent medical leadership across Phase 1-3 clinical programs and partners closely with cross-functional teams including Clinical Operations, Clinical Project Management, Biometrics, Regulatory Affairs, Drug Safety, Translational Medicine, and Preclinical/Clinical Pharmacology.